Synthesis and in vitro efficacy of MMP9-activated NanoDendrons

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 3164-3174

  Samuelson, Lynn E ^a   Scherer, Randy L ^a,b   Matrisian, Lynn M ^a,c   McIntyre, J Oliver ^a,b,c   Bornhop, Darryl J ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

dendrons; drug delivery; MMP9; nanomaterials; paclitaxel; prodrug

Indexed keywords

DOXORUBICIN; GELATINASE B; ILOMASTAT; NANODENDRON; NANOPARTICLE; PACLITAXEL; PEPTIDE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CHEMICAL MODIFICATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINE, TUMOR; DIPEPTIDES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; PACLITAXEL; PRODRUGS; RATS;

EID: 84881337237     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4002206     Document Type: Article

References (44)

1. Kratz, F.; Elsadek, B. Clinical impact of serum proteins on drug delivery J. Controlled Release 2012, 161 (2) 429-45
2. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery: New applications on the horizon J. Controlled Release 2012, 157 (1) 4-28
3. Wolinsky, J. B.; Colson, Y. L.; Grinstaff, M. W. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers J. Controlled Release 2012, 159 (1) 14-26
4. Bremer, C.; Tung, C. H.; Weissleder, R. Molecular imaging of MMP expression and therapeutic MMP inhibition Acadademic Radiology 2002, 9 (Suppl 2) S314-5
5. McIntyre, J. O.; Matrisian, L. M. Molecular imaging of proteolytic activity in cancer J. Cell. Biochem. 2003, 90 (6) 1087-1097
6. McIntyre, J. O. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity Biochem. J. 2004, 377 (Pt 3) 617-28
7. Lebel, R. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model Magn. Reson. Med. 2008, 60 (5) 1056-1065
8. Scherer, R. L.; McIntyre, J. O.; Matrisian, L. M. Imaging matrix metalloproteinases in cancer Cancer Metastasis Rev. 2008, 27 (4) 679-90
9. Scherer, R. L. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon Mol. Imaging 2008, 7 (3) 118-31
10. Jastrzebska, B. New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: From synthesis to in vivo imaging J. Med. Chem. 2009, 52 (6) 1576-1581
11. Jastrzebska, B. Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent Peptides for Youth 2009, 611, 453-454
12. McIntyre, J. O.; Scherer, R. L.; Matrisian, L. M. Near-infrared optical proteolytic beacons for in vivo imaging of matrix metalloproteinase activity Methods Mol. Biol. 2010, 622, 279-304
13. Achilefu, S. Rapid response activatable molecular probes for intraoperative optical image-guided tumor resection Hepatology 2012, 56 (3) 1170-3
14. Akers, W. J. Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe Bioconjugate Chem. 2012, 23 (3) 656-63
15. Wang, J. NIR fluorophore-hollow gold nanosphere complex for cancer enzyme-triggered detection and hyperthermia Peptides for Youth 2013, 765, 323-8
16. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 2002, 295 (5564) 2387-92
17. Liotta, L. A. Metastatic potential correlates with enzymatic degradation of basement membrane collagen Nature 1980, 284 (5751) 67-8
18. McCawley, L. J.; Matrisian, L. M. Tumor progression: Defining the soil round the tumor seed Curr. Biol. 2001, 11 (1) R25-7
19. Martin, M. D.; Matrisian, L. M. Matrix metalloproteinases as prognostic factors for cancer Clin. Lab. Invest. 2005, 28, 16-18
20. Martin, M. D.; Matrisian, L. M. The other side of MMPs: Protective roles in tumor progression Cancer Metastasis Rev. 2007, 26 (3-4) 717-24
21. Acuff, H. B. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment 1 Cancer Res. 2006, 66 (1) 259-266
22. Gorden, D. L. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment Int. J. Cancer 2007, 121 (3) 495-500
23. Martin, M. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background Cancer Res. 2008, 68 (15) 6251-6259
24. Yan, C. H.; Boyd, D. D. Regulation of matrix metalloproteinase gene expression J. Cell. Physiol. 2007, 211 (1) 19-26
25. Kridel, S. J. Substrate hydrolysis by matrix metalloproteinase-9 J. Biol. Chem. 2001, 276 (23) 20572-8
26. Chen, E. I. A residue in the S2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9 J. Biol. Chem. 2003, 278 (19) 17158-63
27. Singal, P. K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 1998, 339 (13) 900-5
28. Airoldi, M. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: A synthetic review Tumori 2011, 97 (6) 690-2
29. Slamon, D. Adjuvant trastuzumab in HER2-positive breast cancer N. Engl. J. Med. 2011, 365 (14) 1273-83
30. Gradishar, W. J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 2005, 23 (31) 7794-7803
31. Malkoch, M.; Malmstrom, E.; Hult, A. Rapid and efficient synthesis of aliphatic ester dendrons and dendrimers Macromolecules 2002, 35 (22) 8307-8314
32. Horton, D, P.W.; Varela, O. Synthesis and antitumor activity of 3′-deamino-3′-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs J. Antibiot. 1984, 37 (8) 853-858
33. Chen, Q.; Sowa, D. A.; Cai, J.; Gabathuler, R. Efficient One-Pot Synthesis of Doxorubicin Conjugates Through Its Amino Group to Melanotransferrin P97 Synth. Commun. 2003, 33 (14) 2401-2421
34. Majoros, I. J. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality Biomacromolecules 2006, 7 (2) 572-9
35. Arcomone, F.C., A.; Cassinellie, G.; Di Marco, A.; Penco, S. Doxorubicin and related compounds. II. Structure-activity consideration Dev. Oncol. 1982, 10, 179-189
36. Albright, C. F. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity Mol. Cancer Ther. 2005, 4 (5) 751-60
37. Nasrolahi Shirazi, A. Design and biological evaluation of cell-penetrating Peptide-Doxorubicin conjugates as prodrugs Mol. Pharmaceutics 2013, 10 (2) 488-99
38. Rudolph-Owen, L. A. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis Cancer Res. 1998, 58 (23) 5500-6
39. Kline, T. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9 Mol. Pharmaceutics 2004, 1 (1) 9-22
40. Law, B.; Tung, C. H. Proteolysis: A biological process adapted in drug delivery, therapy, and imaging Bioconjugate Chem. 2009, 20 (9) 1683-95
41. Choi, K. Y. Protease-activated drug development Theranostics 2012, 2 (2) 156-78
42. Chau, Y.; Tan, F. E.; Langer, R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX Bioconjug. Chem. 2004, 15 (4) 931-41
43. Chau, Y. Investigation of targeting mechanism of new dextran-peptide- methotrexate conjugates using biodistribution study in matrix-metalloproteinase- overexpressing tumor xenograft model J. Pharm. Sci. 2006, 95 (3) 542-51
44. Acuff, H. B. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment Cancer Res. 2006, 66 (1) 259-66